Cited 0 times in
ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-06-02T01:03:46Z | - |
dc.date.available | 2023-06-02T01:03:46Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194626 | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | J. De Langen | - |
dc.contributor.googleauthor | B.C. Cho | - |
dc.contributor.googleauthor | Z. Piotrowska | - |
dc.contributor.googleauthor | X. Le | - |
dc.contributor.googleauthor | S.B. Goldberg | - |
dc.contributor.googleauthor | J.W. Goldman | - |
dc.contributor.googleauthor | I. Okamoto | - |
dc.contributor.googleauthor | N. Hewson | - |
dc.contributor.googleauthor | J. Maidment | - |
dc.contributor.googleauthor | K.H. Tang | - |
dc.contributor.googleauthor | N. Veney | - |
dc.contributor.googleauthor | J. Cosaert | - |
dc.contributor.googleauthor | J. Lau | - |
dc.contributor.googleauthor | M. Dressman | - |
dc.contributor.googleauthor | H. Ambrose | - |
dc.contributor.googleauthor | J.W. Riess | - |
dc.contributor.googleauthor | H.A. Yu | - |
dc.identifier.doi | 10.1016/j.annonc.2022.07.1311 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0923753422031623 | - |
dc.citation.volume | 33 | - |
dc.citation.number | Supplement 7 | - |
dc.citation.startPage | S1091 | - |
dc.citation.endPage | S1092 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.33(Supplement 7) : S1091-S1092, 2022-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.